Horsetalk.co.nz - Full Article
August 2, 2017
Horsetalk.co.nz
A rider from Bahrain has been suspended from competition for six months and fined 2000 Swiss francs after his endurance mount tested positive to five substances not permitted under FEI equine anti-doping rules.
The Bahrain-registered horse Ultreia Larzac, ridden by Othman Abduljaleel Al Awadhi, competed in the CEI2* 120km ride at the Bahrain International Endurance Village, Sakhir, on January 14 this year.
The horse was selected for drug testing. The blood sample revealed the presence of caffeine, theophylline, phenylbutazone, oxyphenbutazone, and dexamethasone.
Caffeine is a central nervous system stimulant. Theophylline is used to open airways in the treatment of respiratory disease. Phenylbutazone and its metabolic byproduct oxyphenbutazone are non-steroidal anti-inflammatory drugs with painkilling effects. Dexamethasone is a corticosteroid drug with anti-inflammatory effects...
Read more at https://www.horsetalk.co.nz/2017/08/02/rider-bahrain-suspension-fine-endurance-horse/#OoSjzXMdLBQybC4j.99
2024: The Year in Endurance
FEI.org - Full Article 20 December 2024 Words by Stacey Stearns Looking back on the highlights of the year... In 2024, Endurance celebr...
-
Inside.fei.org 17 December 2020 The FEI Board took a series of key decisions on allocation, cancellation, and reopening of bids for FEI C...
-
Inside.FEI.org 02 September 2024 Author: Mirjam van Huet A total of 145 athletes and 155 horses are currently preparing for the journe...
-
Inside.FEI.org 29 November 2023 Author: FEI Communications Chilean athletes showcased exceptional performance in the Valparaíso region (...